Background: Proviral load quantification of human T-lymphotropic virus type 1 (HTLV-1) is an essential marker for disease progression. Therefore, accurate and precise quantification of the virus is important. However, many articles published about detection and quantification of HTLV-1 virus neither reported any databank for the pre-validation of their primer and probe sequences nor stressed on its importance. Consequently, this failure may cause proviral load measurement variations of different HTLV-1 strains.
Objective: The aim of this study was to develop a TaqMan assay for HTLV-1 proviral load quantification which is based on a conserved region of tax gene with minimal sequence variability.
Study Design: For the purpose of finding the most conserved region of tax gene, all the HTLV-1 Gene Bank records including tax gene sequence (524 records by December 2009) were aligned in order to design on the most conserved region of this gene. The specificity, sensitivity, inter and intra assay and the dynamic range of the assay were experimentally determined by their respective methodology.
Result: The assay has a dynamic range of 10-10(7) HTLV-1 plasmid DNA/rxn (reaction) and the limit of detection (LOD) less than 10 copies/rxn. The assay gave coefficient of variation (CV) for the Ct values of less than 1% and 4.8% for intra and inter assay, respectively. Clinical sensitivity and specificity were determined to be 97.8% and 100%, respectively.
Conclusion: This TaqMan assay is able to reliably quantify proviral load due to the fact that it has been designed on a conserved region of HTLV-1 tax gene with minimal sequence variability.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.jcv.2011.12.033 | DOI Listing |
Pathogens
December 2024
Laboratory of Global Infectious Diseases Control Science, Graduate School of Agricultural and Life Sciences, The University of Tokyo, 1-1-1 Yayoi, Bunkyo-ku, Tokyo 113-8657, Japan.
The proviral load (PVL) of the bovine leukemia virus (BLV) is a useful index for estimating disease progression and transmission risk. Real-time quantitative PCR techniques are widely used for PVL quantification. We previously developed a dual-target detection method, the "Liquid Dual-CoCoMo assay", that uses the coordination of common motif (CoCoMo) degenerate primers.
View Article and Find Full Text PDFClin Chem
January 2025
Department of Internal Medicine and Pediatrics, HIV Cure Research Center, Ghent University Hospital, Ghent University Ghent, Belgium.
Background: Persistent latent reservoirs of intact HIV-1 proviruses, capable of rebounding despite suppressive antiretroviral therapy (ART), hinder efforts towards an HIV-1 cure. Hence, assays specifically quantifying intact proviruses are crucial to assess the impact of curative interventions. Two recent assays have been utilized in clinical trials: intact proviral DNA assay (IPDA) and quadruplex quantitative PCR (Q4PCR).
View Article and Find Full Text PDFBackground: Bovine leukaemia virus (BLV)-infected Holstein cattle carrying certain bovine leukocyte antigen (BoLA)-DRB3 alleles were previously shown to be resistant to BLV provirus multiplication, while those carrying other alleles were susceptible. This study aimed to determine whether the BoLA-DRB3 alleles carried by BLV-infected cattle could predict proviral load (PVL) and peripheral blood lymphocyte (PBL) count distribution (PVL/PBL distribution).
Methods: Blood samples from Holstein cattle on four dairy farms were tested for the presence of BLV antibodies using a commercial ELISA.
Front Immunol
December 2024
Translational Virology, Department of Medical Microbiology, University Medical Center Utrecht, Utrecht, Netherlands.
Introduction: The main obstacle to achieving an HIV-1 cure is the proviral reservoir. To promote equity in HIV cure strategies, it is crucial to study the viral reservoir of the predominant HIV-1 subtype C in both women and men. Therefore, we investigated the dynamics of the (intact) viral reservoir in relation to plasma viral load (VL), CD4 T cell count, and immune activation before and during 96 weeks of successful antiretroviral therapy (ART).
View Article and Find Full Text PDFFront Immunol
December 2024
Laboratory of Virology, Institute of Biological Sciences, Federal University of Pará, Belém, Brazil.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!